Learning curve of robotic pancreaticoduodenectomy: a CUSUM and risk-adjusted CUSUM analysis of 120 consecutive cases - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Assessing the Learning Curve for Robotic Pancreaticoduodenectomy Using CUSUM and Risk-Adjusted CUSUM in 120 Consecutive Cases

  • By

  • Giuseppe Quero

  • Matteo Aulicino

  • Lodovica Langellotti

  • Gloria Santoro

  • Giuseppe Massimiani

  • Flavia Taglioni

  • Giuseppe Daloiso

  • Roberta Menghi

  • Federica Marzi

  • Antonio Pio Tortorelli

  • Claudio Fiorillo

  • Claudia Ferrantone

  • Davide De Sio

  • Mario Lettieri

  • Rossella Sepe

  • Vincenzo Tondolo

  • Sergio Alfieri

  • October 7, 2026

Share

  • 1

    This retrospective study analyzed prospectively recorded data from 120 consecutive robotic pancreaticoduodenectomies performed from January 2023 through April 2026.

  • 2

    All operations were performed by one surgeon using a standardized, fully robotic Whipple procedure and intracorporeal Child reconstruction.

  • 3

    The study used CUSUM and risk-adjusted CUSUM analyses to assess learning across intraoperative performance, postoperative safety, and oncological adequacy.

  • 4

    The high-volume referral center performed approximately 120 pancreatic resections annually and introduced robotic surgery through a structured, stepwise program.

  • 5

    Major morbidity was defined as a Clavien-Dindo grade III or higher complication within 30 days, and 30- and 90-day mortality were recorded.

Original Source(s)

Learning curve of robotic pancreaticoduodenectomy: a CUSUM and risk-adjusted CUSUM analysis of 120 consecutive cases

  • by Giuseppe Quero, Matteo Aulicino, Lodovica Langellotti, Gloria Santoro, Giuseppe Massimiani, Flavia Taglioni, Giuseppe Daloiso, Roberta Menghi, Federica Marzi, Antonio Pio Tortorelli, Claudio Fiorillo, Claudia Ferrantone, Davide De Sio, Mario Lettieri, Rossella Sepe, Vincenzo Tondolo, Sergio Alfieri

  • October 7, 2026

Related Content

Precision Treatment, Earlier Molecular Detection and De-escalation Transforming Breast Cancer Care

Breast cancer management is becoming increasingly biology-driven, with treatment decisions extending well beyond anatomic stage and conventional receptor classification.

  • by

  • October 14, 2026

  • 6 min
FDA expands bladder cancer therapy approval

The expansion offers another treatment option for patients with high-grade tumors following BCG failure.

AI may predict focal GBM recurrence

Optical analysis of resection-margin tissue identified tumor infiltration as the strongest contributor to predictions of where glioblastoma later recurred.